Elacytarabine – lipid vector technology overcoming drug resistance in acute myeloid leukemia

Author： Burke Aine Carol Giles Frank James

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.12, 2011-12, pp. : 1707-1715

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug Resistance in Childhood Acute Myeloid Leukemia

Current Pharmaceutical Biotechnology, Vol. 8, Iss. 2, 2007-04 ,pp. : 59-75

Bentham Science Publishers

Access to resources Recommend Favorite

Acute Myeloid Leukemia

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 10, 2008-11 ,pp. : 962-962

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Pharmacogenomics in acute myeloid leukemia

By Roumier Christophe Cheok Meyling H

Pharmacogenomics, Vol. 10, Iss. 11, 2009-11 ,pp. : 1839-1851

Future Medicine

Access to resources Recommend Favorite

Immunotherapy in acute myeloid leukemia

Cancer, Vol. 121, Iss. 16, 2015-08 ,pp. : 2689-2704

Blackwell Publishing

Access to resources Recommend Favorite

Immunotherapy of Acute Myeloid Leukemia

Current Pharmaceutical Biotechnology, Vol. 2, Iss. 3, 2001-09 ,pp. : 209-215

Bentham Science Publishers

Access to resources Recommend Favorite